People receiving weight-loss drug Wegovy sustained weight loss for up to four years, shedding an average of 10% of their body weight in that time, as per a new study. Wegrovy is a brand that markets semaglutide injections, that have gained widespread attention for their weight-loss effects. The study also found that Semaglutide injections boost an individual's heart health, even when weight loss doesn't take place.

The study, called SELECT, was published in journal Nature Medicine. "At four years, we see ongoing benefits of semaglutide," said Cheng-Han Chen, MD, interventional cardiologist from Cardiologist, who was not involved in the research. Besides the weight loss, it also lead to a loss in cardiovascular outcomes.

The research was conducted on 17000 adults, who had obesity but did not have diabetes. Overall, people who received once-weekly injections of semaglutide lost on average 10.2% of their body weight over the course of four years. All of the study participants continued to lose weight for about 65 weeks, a year and three months, and then their weight remained at a stable level.

Were There Any Side Effects?

What Did The Results Say?

Of the people on the highest dose of Wegovy, 68% lost at least 5% of their body weight. This compared to 21% of people on the placebo. Additionally, of the total people on Wegovy about 23% lost at least 15% of their body weight. For those in the placebo group, only 1.7% lost that much body weight.

Semaglutide Shows Heart Benefits Beyond Weight Loss

Researchers found that even individuals who did not experience significant weight reduction while on the drug saw a reduced risk of major heart events. Recent analysis of the SELECT trial data revealed that semaglutide significantly lowers the risk of heart attack, stroke, and cardiovascular-related deaths in adults with obesity or those who are overweight. Notably, the results of this study lead the US FDA to approve Novo Nordisk's Wegovy for reducing heart-related risks in this group.

What Is Semaglutide?

Are Their Any Side Effects Of Semaglutide?

Semaglutide, marketed under the brand name Wegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. It is also an anti-obesity drug used for long-term weight management. While it can be taken as a subcutaneous injection or orally, it has significant side effects. It primarily impacts your gastrointestinal tract and its side effects include constipation, nausea, abdominal pain, diarrhoea, and fatigue amongst others.

When the name misleads, the disease remains misunderstood. Hence, endocrinologists now propose renaming PCOS as Polyendocrine Metabolic Ovarian Syndrome or PMOS.

This is because the term “Polycystic Ovarian Syndrome” is considered a misnomer. The name makes it sound like the condition is only related to the ovaries. However, over 30% of such patients have normal ovaries. The root lies in the hypothalamus, pituitary, adrenals, pancreas, and adipose tissue — truly polyendocrine.

The cysts in the name are actually antral follicles. The real burden is insulin resistance, dyslipidemia, NAFLD, and a 2-fold higher cardiovascular risk by age 50.

Not just reproductive: PCOS is India’s commonest endocrine disorder — 1 in 5 young women. It drives diabetes, hypertension, depression, and infertility.

PMOS, the acronym, expands as:

P — Polyendocrine: HPO axis + adrenal + insulin + leptin dysfunction

M — Metabolic: Insulin Resistance, obesity, fatty liver, CVD risk

O — Ovarian: Anovulation, hyperandrogenic ovarian dysfunction remains key

S — Syndrome: Heterogeneous, lifelong

This aligns with the 2023 International PCOS Guideline that defines it as a “metabolic + reproductive + psychological disorder”. Yet patients are still told, “You just have cysts.” PMOS reminds every physician to check OGTT, lipids, BP, and mental health at age 18, not 45.

The bottom line is that by changing the name, it is possible to change the game. When a 16-year-old hears “Polyendocrine Metabolic Ovarian Syndrome”, she understands it’s not vanity or infertility alone.

India is better prepared to deal with potential Hantavirus outbreaks due to the healthcare infrastructure and quarantine systems established during the COVID-19 pandemic, according to Dr NK Ganguly, former Director General of the Indian Council of Medical Research (ICMR).

In an exclusive interview with HealthandMe, Dr Ganguly said that while isolated cases of Hantavirus have appeared in India in the past, especially in crowded peri-urban and urban settings in Kerala, large-scale outbreaks have largely been reported in countries such as China, Argentina, the UK, and the US.

Dr Ganguly said that India's healthcare system significantly improved after the deadly COVID pandemic.

“India is overprepared in a way that during the COVID-19, our system, even at the district level or in much more rural settings, got established,” he said.

He pointed out that hospitals now have access to ECMO, BPAP systems, ventilators, and oxygen management facilities to curb the spread in case of an outbreak.

Dr Ganguly also mentioned the availability of antiviral drugs and experimental vaccine efforts that could potentially be explored for hantavirus treatment. “There are some crude vaccines which are made here also,” he said.

He added that India’s quarantine systems and public health drills developed during COVID-19 would also help contain future outbreaks.

“I think India will be okay because of the sheer transmission dynamics of this virus,” he said.

Hantavirus is a zoonotic disease that primarily gets transmitted through contact with infected rodents or exposure to their urine, droppings, and saliva, though rare cases of person-to-person transmission have also been reported.

According to the World Health Organization (WHO), 11 cases — including three deaths — have been confirmed so far. However, additional suspected and confirmed cases are likely to emerge across countries.

Also read: Hantavirus Can Linger Indoors, Spread Through Contaminated Dust, Says Infectious Disease Expert

Importance Of One Health

The One Health approach is critical in understanding and containing outbreaks like hantavirus, Dr Ganguly said.

The One Health approach, which integrates human health, animal health, and environmental monitoring, is also crucial to target the emerging infectious diseases, he noted.

Further, the noted microbiologist stressed the importance of strengthening surveillance across humans, animals, and the environment.

He explained that disease surveillance requires collaboration between bird specialists, forest experts, environmental scientists, and mammologists, especially for tracking zoonotic infections such as avian flu and hantavirus.

“In avian flu, birds follow special migration routes, so we needed bird specialists, forest experts, environmental experts, and mammologists,” Dr Ganguly said.

The expert also highlighted the growing challenge posed by shrinking spaces between humans and animals and the role of antimicrobial resistance (AMR) in emerging disease threats.

“Animal health is equally important. We need to maintain them, track their movements, and do surveillance,” he said.

Need To Track Climate

Dr Ganguly also warned that rising temperatures and shrinking boundaries between humans and animals could increase the risk of future infections.

“It is an environmental infection. With the rise of temperature, more hantavirus infections occur,” he told HealthandMe.

Why India Must Boost Surveillance

Calling surveillance one of the most critical tools in outbreak prevention, he urged India to strengthen monitoring systems for animals, vectors, and humans alike.

“We need to set up a dedicated surveillance for hantavirus in India, and we need to track hantavirus,” he said.

Dr Ganguly explained that to date, hantavirus cases in India have been detected accidentally during testing for respiratory infections or flu-like illnesses using advanced panel-based diagnostic systems.

“Like now these days, what happens is that when you are getting respiratory infection or flu-like symptoms, they put up a test system which is known as bio-fire or a thing like that which identifies 26 panels and gives the CT scoring of that, so from there, hantavirus emerged,” he said.

He added that India should strengthen surveillance tools and continue monitoring infections in animals, vectors, and humans alike.

Prateek Yadav (38), the son of late Samajwadi Party founder Mulayam Singh Yadav, died due to a massive blockage in the blood vessels of the lungs, leading to a collapse of the heart and respiratory system, as revealed in the postmortem examination report.

According to the autopsy findings, the provisional cause of death was recorded as “cardiorespiratory collapse due to massive pulmonary thromboembolism.” In simple terms, doctors said a large blood clot had blocked blood flow to the lungs, causing his heart and breathing to fail.

What Is Pulmonary Thromboembolism?

An embolism is any object (clot, fat, air, tissue) traveling through the bloodstream that becomes stuck, blocking blood flow. A thromboembolism is a specific type of embolism where that travelling object is a piece of a blood clot (thrombus) that has broken off from its original site.

It is a life-threatening condition that happens when a blood vessel in the lungs is blocked by a blood clot.

The common symptoms may include:

• Difficulty in breathing
• Chest pain
• Cough up blood

The blood clot starts in a deep vein in the leg and travels to the lung in most cases. Rarely, the clot forms in a vein in another part of the body, noted Mayo Clinic. When a blood clot forms in one or more of the deep veins in the body, it is called a deep vein thrombosis or DVT.

Other symptoms of pulmonary embolism include:

• irregular heartbeat
• lightheadedness or dizziness
• excessive sweating
• fever
• leg pain or swelling, usually in the back of the lower leg
• clammy or discolored skin

Also read: Your Desk Jobs May Impact Fertility, Not Just Waistlines, Say Experts

Lung Infection Claims Life of Karnataka Minister

Meanwhile, Karnataka's Planning and Statistics Minister, D. Sudhakar (66), passed away after a prolonged battle with a lung infection.

The most common lung infections that people experience are pneumonia, bronchitis, tuberculosis, influenza-related infections, and severe viral illnesses.

Experts noted that these lung infections cause fluid or pus to fill the air sacs, which prevents oxygen from entering the bloodstream.

"What may initially appear as a routine cough, fever, or chest infection can progress to severe pneumonia, respiratory failure, sepsis, or permanent lung damage,” Dr. Vikas Mittal, Director - Pulmonologist, CK Birla Hospital, Delhi, told HealthandMe.

Warning signs include

• worsening breathlessness,
• persistent fever,
• chest pain,
• bluish lips,
• confusion,
• falling oxygen levels should never be ignored.

Dr. Nikhil Rajvanshi, Consultant - Paediatric Pulmonology, Rainbow Hospital, Delhi, told HealthandMe that children may be more at risk of pulmonary infections as they can become dangerous quickly because their lungs and immune systems are still developing.

Common illnesses such as bronchiolitis, pneumonia, influenza, and other viral infections may rapidly lead to breathing difficulty, low oxygen levels, dehydration, and respiratory distress. Infants, premature babies, malnourished children, and those with asthma or congenital disorders are at higher risk of complications.

The experts called for

• early medical evaluation
• timely treatment
• vaccination
• good hygiene practices,
• quit smoking,
• maintaining immunity.